A Phase 1 interventional study of Hydronidone capsules and Placebo capsules in Liver Fibrosis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.
Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 59th largest by enrollment of the 127 interventional ones that give a count, is one of 19 that started in 2025, is one of 11 in phase 1, and was the 184th registered.
1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:
Fifth Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18+
Air Force Military Medical University, China · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–80
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Sites in China
Ages 30–80
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 25 · Phase 3 12 · Phase 4 22
First in 2005; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 120 across the 127 interventional studies, 430 across the 86 observational. Of the 60 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 214 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Continent Pharmaceutical Co, Ltd., one of the names counted as GNI Group Ltd.. Under that name alone:
Beijing Continent Pharmaceutical Co, Ltd. is the lead sponsor of 26 studies on the registry; 7 are open to participants now.
GNI Group Ltd. has 6 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Liver Cirrhosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06779058Shengjing HospitalMR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B | 2026-12-01 |
| NCT06770283Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySpirulina Tablets Treat Liver Fibrosis/Cirrhosis | 2026-12-26 |
| NCT07252102Zhejiang UniversityEffect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients | 2026-12-28 |
| NCT05974904Chongqing Medical UniversityAssociation of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study | 2026-12-28 |
| NCT06762223Xiqiao ZhouHenagliflozin on Liver Fibrosis in Patients with MASLD and T2DM | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 214 studies in Liver Cirrhosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Based on the Phase I (Ia, Ib, Ic) clinical pharmacokinetic study of Hydronidone Capsules, a clinical pharmacokinetic trial of Hydronidone Capsules (specification: 30 mg/capsule) was conducted, including single-dose administration, multiple-dose administration, and a food-effect study. The aim was to investigate the safety, tolerability, and pharmacokinetic characteristics of higher doses of Hydronidone Capsules (specification: 30 mg/capsule) in healthy subjects, in preparation for future expansion of indications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On the morning of D1, the patients took 180mg of hydronidone capsules orally on an empty stomach once.
Drug: Hydronidone capsules
On the morning of D1, the patients took 120mg of hydronidone capsules orally on an empty stomach once.
Drug: Hydronidone capsules
On the morning of D1, the patients took 240mg of hydronidone capsules orally on an empty stomach once.
Drug: Hydronidone capsules
On the morning of D1, the patients took 300mg of hydronidone capsules orally on an empty stomach once.
Drug: Hydronidone capsules
On the morning of D1, the patients took 360mg of hydronidone capsules orally on an empty stomach once.
Drug: Hydronidone capsules
On the morning of D1, the patients took 420mg of hydronidone capsules orally on an empty stomach once.
Drug: Hydronidone capsules
Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.
Drug: Hydronidone capsules
Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.
Drug: Hydronidone capsules
Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.
Drug: Hydronidone capsules
Period 1 involved administration under fasting conditions, with a 7-day washout period starting on Day 2. Administration for Period 2 was conducted on Day 8.
Drug: Hydronidone capsules
In Period 1, a high-fat meal was consumed first, followed by drug administration within 30 minutes, with washout commencing on Day 2. After a total 7-day washout period, the second period of dosing was administered on Day 8.
Drug: Hydronidone capsules
On the morning of D1, the patients took 180mg of hydronidone capsules orally on an empty stomach once.
Drug: Placebo capsules
Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.
Drug: Placebo capsules
SAD:Single-dose administration MAD:Multiple-dose group Study on the Interaction between Food and Drugs
SAD:Single-dose administration MAD:Multiple-dose group Study on the Interaction between Food and Drugs
SAD :Blood drug PK parameters(Cmax)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(Tmax)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(AUC0-t)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters( t1/2)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(AUC0-∞)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(λz)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(Vd/F)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(CL/F)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(AUC_%Extrap)
Time frame: 24 hours after administration
SAD:Blood drug PK parameters(MRT)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(ss)
Time frame: 24 hours after administration
MAD :Blood drug PK parameters(Cmax)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(Tmax)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(AUC0-t)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters( t1/2)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(AUC0-∞)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(λz)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(Vd/F)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(CL/F)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(AUC_%Extrap)
Time frame: 24 hours after administration
MAD:Blood drug PK parameters(MRT)
Time frame: 24 hours after administration
The influence of food on the parameters of single-dose pharmacokinetics(Tlag)
Time frame: 24 hours after administration
The influence of food on the parameters of single-dose pharmacokinetics(Cmax)
Time frame: 24 hours after administration
The influence of food on the parameters of single-dose pharmacokinetics(Tmax)
Time frame: 24 hours after administration
The influence of food on the parameters of single-dose pharmacokinetics(AUC0-t)
Time frame: 24 hours after administration
The influence of food on the parameters of single-dose pharmacokinetics(AUC0-∞)
Time frame: 24 hours after administration
Hydronidone and its metabolites M3 and M4 blood drug concentrations (SAD)
Time frame: 24 hours after administration
Hydronidone and its metabolites M3 and M4 blood drug concentrations (MAD)
Time frame: 24 hours after administration
Safety indicator: Any adverse event
Adverse Event (AE) is defined as any untoward medical occurrence during drug clinical trials, drug therapy, or medical procedures, regardless of its causal relationship to the drug used.
Time frame: 48 hours after administration
Safety indicators:Chest X-ray examination
Time frame: 48 hours after administration
Safety indicators:12-lead electrocardiogram examination.
The 12-lead electrocardiogram records the electrical activity of the heart through 12 different lead positions, and is the most commonly used and fundamental non-invasive examination method for diagnosing heart diseases.A 12-lead ECG examines P waves, PR intervals, QRS complexes, ST segments, T waves, QT intervals, and other ECG waves and intervals.
Time frame: 48 hours after administration
Ran from Dec 2025 to primary completion in May 2026, 5 months.
Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydronidone
Beijing Continent Pharmaceutical Co, Ltd. →